Point-of-care ultrasound scan as the primary modality for evaluating parotid tumors

Jennifer L. Harb MD1,2 | Christopher Zaro BA3 | Samih J. Nassif MD1 | Jagdish K. Dhingra MD1,4

1Department of Otolaryngology-Head and Neck Surgery, Tufts Medical Center, Boston, Massachusetts, USA
2University of Miami Miller School of Medicine, Miami, Florida, USA
3University of Massachusetts T.H. Chan School of Medicine, Worcester, Massachusetts, USA
4ENT Specialists, Brockton, Massachusetts, USA

Correspondence
Jagdish K. Dhingra, ENT Specialists, 35 Pearl Street, 2nd floor, Brockton, MA 02301, USA.
Email: jdhingra@entspecialists.com

Abstract

Objectives: This study aimed to explore ultrasonography as a single imaging modality for the initial assessment of parotid lesions compared to computed tomography (CT) and magnetic resonance imaging (MRI).

Methods: A retrospective cross-sectional study was performed on 264 parotid gland lesions evaluated in a dedicated point-of-care ultrasound (POCUS) clinic with concurrent fine needle biopsy (FNB). Two hundred and nine of these lesions also underwent CT or MRI imaging. Histopathology results, when available, were recorded and compared to imaging impressions.

Results: Surgeon-performed POCUS classified parotid masses accurately when compared to final histopathology (90/96, 94%). Using predefined criteria, POCUS determined the nature of parotid lesions more definitively than the descriptive CT or MRI radiology reports (p<.001). Sub-analysis showed that ultrasonography was able to distinguish between benign pathologies with high degree of accuracy (Warthin tumor—82%, pleomorphic adenoma—64%).

Conclusions: POCUS can accurately distinguish between benign and malignant parotid lesions. POCUS may suffice as the only imaging study for benign lesions, obviating the need for additional cross-sectional imaging. This can be combined with fine needle or core biopsy in the same visit, resulting in expedient diagnosis, low cost, and lack of radiation exposure.

Level of Evidence: 2b, individual cross-sectional cohort study.

KEYWORDS
fine needle aspiration, fine needle biopsy, parotid, ultrasound

1 | INTRODUCTION

Salivary gland tumors comprise 3%–6% of all head and neck neoplasms, approximately 85% of which originate in the parotid gland.1–3 Preoperative imaging and fine needle biopsy (FNB) are often performed to assist with appropriate counseling and surgical planning.3

Ultrasoundography (US) has been used as the primary imaging modality for parotid mass evaluation in much of Europe and Asia, whereas computed tomography (CT) and magnetic resonance imaging...
(MRI) is routinely the first-line modality in the United States.\(^2,5\) Ninety percent of parotid tumors arise in the superficial lobe, rendering them amendable to US assessment.\(^3,4,6,7\) On US, benign tumors generally demonstrate deep enhancement and a homogenous hypoechoic structure, regular and well-defined borders, and demarcated vessel distribution.\(^6,8,9\) (Figure 1). Conversely, malignant lesions may have a heterogenous structure with irregular borders and extra-parenchymal spread into adjacent structures, or diffuse and poorly demarcated perfusion patterns.\(^6,8,9\) (Figure 2). Internal necrosis, cystic change, and lymph node involvement may also be seen.\(^4\)

The sternocleidomastoid m., posterior belly of the digastic m., masseter m., retromandibular vein, and mandible are helpful in localizing masses on US.\(^10\) The retromandibular vein is a reliable surrogate marker for the facial nerve, thereby distinguishing between superficial and deep lobe tumors.\(^8\) However, deep lobe tumors or those near the mandible condyle may be shielded by the overlying parotid gland or nearby bone, rendering US less effective in these cases.\(^2,9\) In cases where there is concern for perineural spread, skull base or bony involvement, or extra-parenchymal spread, CT, and MRI are effective tools for further classification.\(^2-4,11,12\)

Economically, US is less expensive than both CT and MRI. As of August 2021, the Medicare reimbursement for a soft tissue neck CT with contrast averaged $245 and a head/neck MRI with and without contrast cost $473, whereas a head and neck US cost $118.\(^13\) There are also well-described allergic reactions and nephrotoxic effects from the contrast dye used in CT and MRI, as well as potential carcinogenic effects of cumulative radiation exposure from repeat CT imaging.\(^14\)

Our study hypothesizes that surgeon-performed point-of-care ultrasound (POCUS) should be the initial and, in many cases, the only imaging study needed for workup of parotid lesions, obviating the need for CT or MRI.

## 2 METHODS

The Tufts Medical Center Institutional Review Board approved this study.

A retrospective cross-sectional chart review was performed on all patients referred to a dedicated US clinic in a busy community otolaryngology practice between 2014 and 2021. The site is certified by the American Institute of Ultrasound Medicine (AIUM). All POCUS and US-guided FNBs were performed by the lead author with training and certification in head and neck US courses sponsored by the American College of Surgeons and American Thyroid Association. The senior author has more than 8 years’ experience performing these procedures.

Each US was performed with a 7.5–10 MHz linear probe. In addition to B-mode, US color-flow imaging was utilized. Scans and procedures were performed in a supine position with slight neck extension in a standard reclining examination chair. Scans are performed in transverse and longitudinal/oblique planes; depth and grain were adjusted for each lesion for optimal viewing. Photographs were taken of each lesion. FNBs under US guidance were performed during this same visit with a 27-gauge needle.

When evaluating each lesion’s US image, the operator was blinded to any previously available CT- or MRI-radiologist impression as well as any available histopathology. Lesions were classified as benign, malignant, or indeterminate based on US characteristics such as echogenicity, vascularity, border clarity, multicentricity, and location. Benign lesions were further subclassified into Warthin tumor, pleomorphic adenoma, lymph node, or cyst. Criteria used by the operator are detailed in Table 1. The CT and/or MRI imaging characteristics and the radiologist impressions of benign versus malignant were recorded when available. Radiology reports were evaluated from five different radiology departments at surrounding community hospitals.

Imaging results from all three modalities were then compared to the final surgical histopathology. The number of lesions identified as benign or malignant on both imaging and final surgical histopathology were recorded, as were the lesions whose imaging characteristics
were discordant from their final histopathology results. The accuracy of determining benign or malignant was calculated as a percentage for each imaging modality. These averages were then compared for each imaging modality using a chi-square test. An additional calculation was performed to assess the percent accuracy of US in identifying Warthin tumor and pleomorphic adenomas compared to histopathology.

### RESULTS

Over an 8-year period, 265 parotid fine needle aspirations were performed utilizing POCUS in a dedicated US clinic in an office setting within a single large community otolaryngology practice. Of these, 79% (n = 209) also underwent additional cross-sectional imaging—CT or MRI. The patients’ ages ranged from 33 to 90; 104 subjects were female, 105 were male.

Of these 209 patients with cross-sectional imaging results, 67% (n = 140) of patients underwent a CT scan, 21% (n = 44) underwent an MRI, and 12% (n = 25) underwent both. One-hundred and eighteen of these 209 masses ultimately underwent excision and therefore had final pathology available. Of the 118 surgically excised lesions, 34 had been determined benign on CT/MRI (29%), 13 malignant (11%), and 71 indeterminate (60%). When correlating with final pathology, 31/34 were accurately called benign (negative predictive value [NPV] 91%), 7/13 were accurately called malignant (positive predictive value [PPV] 54%), and 9/47 were discordantly called benign or malignant (19%) (Table 2).

All patients in our study underwent POCUS. Of the 118 lesions that ultimately underwent surgical excision, 96 (81%) were classified as benign on US and 21 (18%) were suspicious for malignancy. One lesion was classified as “indeterminate” (1%). When correlating with final pathology, 90/96 were accurately called benign (NPV 94%), 17/21 were accurately called malignant (PPV 81%), and 10/117 were discordantly deemed benign or malignant (9%) (Table 2).

A chi-square test was performed to compare the rate of lesions accurately labeled benign and malignant by POCUS and CT/MRI, with surgical histopathology as the gold standard. Taken in sum, POCUS was able to determine a benign or malignant lesion more accurately than the CT/MRI radiology report description (p < .001, Table 2).

### TABLE 1

| Features suggestive of malignancy                                                                 |       |
|--------------------------------------------------------------------------------------------------|-------|
| Ill-defined borders                                                                                |       |
| Lack of homogeneity                                                                               |       |
| Invasion into nearby structures                                                                   |       |
| Lymph node enlargement                                                                            |       |
| Disorganized color pattern                                                                        |       |

### TABLE 2

| US | Final surgical histopathology matched | US impression total | CT/MRI | Final surgical histopathology matched | CT/MRI impression total | p-value |
|----|--------------------------------------|---------------------|--------|--------------------------------------|-------------------------|----------|
| Benign | 90                                 | 96                  | 31     | 34                                   | 101                     | <.001    |
| Malignant | 17                                 | 21                  | 7      | 13                                   | 54                      | .09      |
| Indeterminate | 1                                |                     |        |                                      |                         |          |
| Overall | 107                                | 118                 | 38     | 101                                  |                         | .61      |

### TABLE 3

| US appearance determination | n   | Surgical histopathology correlated | Other benign tumor on histopathology | Malignant tumor on histopathology |
|------------------------------|-----|-----------------------------------|------------------------------------|----------------------------------|
| Pleomorphic adenoma          | 42  | 27 (64%)                          | 11 (26%)                           | 4 (10%)                          |
| Warthin’s tumor              | 44  | 36 (82%)                          | 6 (14%)                            | 2 (4%)                           |
| Other (cyst, lymph node, etc.)| 9   | 6 (67%)                           | 2 (22%)                            | 1 (11%)                          |
An additional analysis was performed on the parotid lesions consid-
ered benign on US (n = 95). The likely benign lesions were further clas-
sified into three categories—pleomorphic adenoma, Warthin’s tumor, or
other, which included lymph nodes or purely cystic lesions. Forty-two
were considered likely to be a pleomorphic adenoma, 44 were consid-
ered Warthin’s tumors, and 9 were classified as “other.” When com-
pared to final surgical pathology, 64% (n = 27) were accurately called
pleomorphic adenomas, 82% (n = 36) were accurately called Warthin
tumors, and 67% (n = 6) were accurately called “other.” Twenty percent
(n = 19) of the 95 were classified as another type of benign tumor on
preoperative US assessment (Table 3).

4 | DISCUSSION

Twenty to thirty percent of parotid tumors are malignant, and there-
fore preoperative assessment is critical for ensuring proper manage-
ment. US is less commonly used in the United States than in Europe
and Asia, where this modality is often the first diagnostic test for
parotid pathology. Our study suggests that surgeon-performed
POCUS is an effective tool in determining the nature of parotid
lesions, saving patients from the financial, time-related, and radiation
burdens of CT/MRIs.

In our study, we compared the ability of US and cross-sectioning
imaging (CT and MRI) to discern the benign or malignant potential of
parotid lesions. Very few CT or MRI reports provided a determination
of benign vs. malignant, often listing both as possibilities. The role of
the radiologist is not necessarily to make a diagnosis of malignant or
benign; as a result, many CT and MRI reports were descriptive in nature,
looking at factors such as location, size, density, and enhancement of
the lesion.

When a benign determination was made on cross-sectional imag-
ing, our study found that these assessments were generally concor-
dant with final histopathology, when available (31 of 34 lesions, 91%;
Table 2). Similarly, surgeon-led POCUS was also found to be highly
accurate in assessing the benign potential of lesions when compared
to final histopathology (90 of 96 lesions, 94%, Table 2). This difference
was not found to be statistically significant (p = .61). The assessment
of malignant potential differed between the modalities but did not
reach statistical significance (p = .92): US demonstrated an 81% accu-
6

racy rate (17 of 21 lesions) versus 54% with CT/MRI (7 of 13 lesions).

However, these values fail to include the substantial number of
lesions labeled indeterminate on cross-sectioning imaging (54 of
101 lesions, 54%). Comparatively, only one lesion was labeled indeter-
minate on POCUS (1 of 118, 1%). When accounting for these lesions,
our study found that overall accuracy in determining benign or mali-
gnant potential on imaging differed significantly (p < .001); US rate was
90% (107 of 118 lesions) versus the CT/MRI rate of 38% (38 of
101 lesions; Table 2).

Cross-sectional imaging is warranted for the assessment of
parotid lesions in select instances. CT and/or MRI may better deline-
ate deep tumors or those with suspected perineural spread or bony
invasion. Its use in further classifying and determining the extent of
malignant tumors can be critical to preoperative planning. However,
we advocate for the judicious use of cross-sectional imaging, given
the expense and proven effectiveness of US in evaluating such
lesions. Additionally, cross-sectional imaging quality may be compro-
mised by motion artifact, artifact from dental fillings or implants, or
patients who are intolerant to loud noise or are claustrophobic.

Our study showed that a substantial number of cross-sectional
imaging radiology reports were descriptive in nature rather than sug-
gestive of benign or malignant potential. In practice, this requires the
surgeon to view the images him/herself to assess this potential and
plan surgical intervention accordingly. Given that both US and cross-
sectional imaging require surgeon interpretation for planning, the
authors advocate for surgeon-led POCUS, which can expedite care
while also allowing for diagnostic sampling via FNB during the same
visit, if warranted.

In our benign lesion sub-analysis (Table 3), our study suggests that
some pathologies may be accurately predicted based on US charac-
teristics (Table 1). Pleomorphic adenomas are hypoechoic, homogenous, well-
defined, lobulated with posterior acoustic enhancement, and are poorly or
peripherally vascularized on Doppler US; in our study, 67% of pleomor-
phic adenomas were accurately identified on preoperative US. Warthin
tumors may be bilateral or multiple in 15% of patients, rounded or lobu-
lated, hypoechoic, and may show cystic change with internal septation
and hypervascularity on Doppler US. In our study, 88% of Warthin
tumors were accurately predicted on preoperative US. Cysts may demon-
strate classic smooth borders and are anechoic, while benign intra-
parotid lymph nodes can be identified by an intact hilum and ovoid shape.

There are several strengths to this study. All lesions were assessed
by US by single operator, eliminating the variability in US-operator abil-
ity. This single operator (lead author) adhered to the characteristics in
Table 1 to classify masses as benign or malignant. Every lesion included
in the study also had final histopathologic data, the gold standard in
characterizing malignant potential. There are several limitations to the
study; while one operator limits variability, numerous operators could
improve the inter-operator reproducibility of the results. Additionally,
increasing our n would perhaps allow for greater statistical significance.

Some reports suggest POCUS is subject to operator skill, and that
otolaryngologists fear performing their own radiographic assessments
and prefer to rely on those performed in radiology departments. Indeed,
there may be some hesitation from otolaryngologists toward incorpo-
rating US into the practice, particularly as a sole imaging
modality for characterizing parotid masses. However, there are
umerous well-established US training courses and certification pro-
grams to gain experience. Furthermore, the authors believe that sur-
geons are particularly well-equipped to interpret US, as a thorough
knowledge of anatomy is paramount.

5 | CONCLUSION

POCUS of is an inexpensive, low-risk, and effective tool for evaluating
parotid lesions. Its accuracy in predicting the nature of salivary gland
lesions compares favorably to that of cross-sectional imaging. More-
over, US can accurately localize these lesions by identifying adjacent
structures such as the sternocleidomastoid m., digastric m., and retro-mandibular v. FNB can be performed at the same visit, thus expediting care. For deep masses or malignant lesions with suspected local invasion or perineural spread, CT or MRI should be performed. Our study suggests that POCUS can often be confidently used as an initial, and perhaps sole, imaging modality for parotid masses without adverse features.

ORCID
Jennifer L. Harb https://orcid.org/0000-0002-8485-5764
Christopher Zaro https://orcid.org/0000-0001-8468-8727
Samih J. Nassif https://orcid.org/0000-0001-9557-0302
Jagdish K. Dhingra https://orcid.org/0000-0001-6774-5558

REFERENCES
1. Liu CC, Jethwa AR, Khariwala SS, Johnson J, Shin JJ. Sensitivity, specificity, and posttest probability of parotid fine-needle aspiration: a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2016;154:9-23.
2. Moore MG, Yueh B, Lin DT, Bradford CR, Smith RV, Khariwala SS. Controversies in the workup and surgical management of parotid neoplasms. Otolaryngol Head Neck Surg. 2020;164:27-36.
3. Afzelius P, Nielsen MY, Ewertsen C, Bloch KP. Imaging of the major salivary glands. Clin Physiol Funct Imaging. 2016;36:1-10.
4. Lee YYP, Wong KT, King AD, Ahuja AT. Imaging of the major salivary glands. Clin Physiol Funct Imaging. 2016;36:1-10.
5. Liang YY, Xu F, Guo Y, Wang J. Diagnostic accuracy of magnetic resonance imaging techniques for parotid tumors, a systematic review and meta-analysis. Clin Imaging. 2018;52:36-43.
6. Cantisani V, David E, Sidhu PS, et al. Parotid gland lesions: multiparametric ultrasound and MRI features. Ultraschall Med. 2016;37:454-471.
7. Prasad RS. Parotid Gland Imaging. Otolaryngol Clin North Am. 2016;49:285-312.
8. Zheng M, Plonowska KA, Strohl MP, Ryan WR. Surgeon-performed ultrasound for the assessment of parotid masses. Am J Otolaryngol. 2018;39:467-471.
9. Cicero G, D’Angelo T, Racchiua S, et al. Cross-sectional imaging of parotid gland nodules: a brief practical guide. J Clin Imaging Sci. 2018;8:14.
10. Mantzopoulos K, Tshaikowsky N, Goncalves M, Mueller SK, Iro H. Evaluation of preoperative ultrasonography in the differentiation between superficial and deep parotid gland tumors. Ultrasound Med Biol. 2020;46:2099-2103.
11. Koyuncu M, Seşen T, Akan H, et al. Comparison of computed tomography and magnetic resonance imaging in the diagnosis of parotid tumors. Otolaryngol Head Neck Surg. 2003;129:726-732.
12. Rudack C, Jörg S, Kloska S, Stoll W, Thiede O. Neither MRI, CT nor US is superior to diagnose tumors in the salivary glands—an extended case study. Head Face Med. 2007;3:19.
13. Medicare.gov. Procedure Price Lookup for Outpatient Services. August 1, 2021. Accessed February 15, 2022. https://www.medicare.gov/procedure-price-lookup/cost/70553/
14. Seeram E. Computed tomography: a technical review. Radiol Technol. 2018;89(3):279CT-302CT.
15. Costache A, Dumitru M, Anghel I, Cergan R, Anghel AG, Sarafoleanu C. Ultrasonographic anatomy of head and neck—a pictorial for the ENT specialist. Med Ultrason. 2015;17:104-108.

How to cite this article: Harb JL, Zaro C, Nassif SJ, Dhingra JK. Point-of-care ultrasound scan as the primary modality for evaluating parotid tumors. Laryngoscope Investigative Otolaryngology. 2022;7(5):1402-1406. doi:10.1002/lio2.887